<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:51:05Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10382113" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10382113</identifier>
        <datestamp>2023-07-29</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="jah38582" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10382113</article-id>
              <article-id pub-id-type="pmcid">PMC10382113</article-id>
              <article-id pub-id-type="pmc-uid">10382113</article-id>
              <article-id pub-id-type="pmid">37449567</article-id>
              <article-id pub-id-type="pmid">37449567</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.123.029588</article-id>
              <article-id pub-id-type="publisher-id">JAH38582</article-id>
              <article-id pub-id-type="other">JAHA/2023/029588</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Coronary Heart Disease</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Association Between <styled-content style="fixed-case" toggle="no">Claims‐Defined</styled-content> Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the <styled-content style="fixed-case" toggle="no">EXTEND‐DAPT</styled-content> Study</article-title>
                <alt-title alt-title-type="right-running-head"><styled-content style="fixed-case" toggle="no">Frailty‐Associated</styled-content> Outcomes in the <styled-content style="fixed-case" toggle="no">DAPT</styled-content> Study</alt-title>
                <alt-title alt-title-type="left-running-head">Faridi et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah38582-cr-0001" contrib-type="author">
                  <name>
                    <surname>Faridi</surname>
                    <given-names>Kamil F.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9276-9110</contrib-id>
                  <xref rid="jah38582-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0002" contrib-type="author">
                  <name>
                    <surname>Strom</surname>
                    <given-names>Jordan B.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6592-6141</contrib-id>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0003" contrib-type="author">
                  <name>
                    <surname>Kundi</surname>
                    <given-names>Harun</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0303-9619</contrib-id>
                  <xref rid="jah38582-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0004" contrib-type="author">
                  <name>
                    <surname>Butala</surname>
                    <given-names>Neel M.</given-names>
                  </name>
                  <degrees>MD, MBA</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6937-4041</contrib-id>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38582-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0005" contrib-type="author">
                  <name>
                    <surname>Curtis</surname>
                    <given-names>Jeptha P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6872-0501</contrib-id>
                  <xref rid="jah38582-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0006" contrib-type="author">
                  <name>
                    <surname>Gao</surname>
                    <given-names>Qi</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-8243-1052</contrib-id>
                  <xref rid="jah38582-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0007" contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>Yang</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0008" contrib-type="author">
                  <name>
                    <surname>Zheng</surname>
                    <given-names>Luke</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8468-4590</contrib-id>
                  <xref rid="jah38582-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0009" contrib-type="author">
                  <name>
                    <surname>Tamez</surname>
                    <given-names>Hector</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0010" contrib-type="author">
                  <name>
                    <surname>Shen</surname>
                    <given-names>Changyu</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4444-0943</contrib-id>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38582-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0011" contrib-type="author">
                  <name>
                    <surname>Secemsky</surname>
                    <given-names>Eric A.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3861-3163</contrib-id>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah38582-cr-0012" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Yeh</surname>
                    <given-names>Robert W.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0564-4468</contrib-id>
                  <xref rid="jah38582-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="jah38582-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <address>
                    <email>ryeh@bidmc.harvard.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah38582-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Section of Cardiovascular Medicine, Department of Medicine</named-content>
                <institution>Yale School of Medicine</institution>
                <city>New Haven</city>
                <named-content content-type="country-part">CT</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38582-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine</named-content>
                <institution>Beth Israel Deaconess Medical Center</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38582-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Cardiology</named-content>
                <institution>Ankara City Hospital</institution>
                <city>Ankara</city>
                <country country="TR">Turkey</country>
              </aff>
              <aff id="jah38582-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Cardiology Division, Department of Medicine</named-content>
                <institution>Massachusetts General Hospital, Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38582-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Baim Institute for Clinical Research</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="jah38582-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Biogen</institution>
                <city>Cambridge</city>
                <named-content content-type="country-part">MA</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence to: Robert W. Yeh, MD, MSc, Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Division of Cardiovascular Disease, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, Boston, MA 02215. Email: <email>ryeh@bidmc.harvard.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>14</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>18</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <volume>12</volume>
              <issue seq="130">14</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v12.14</issue-id>
              <elocation-id>e029588</elocation-id>
              <history>
                <date date-type="received">
                  <day>24</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>31</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell-->
                <copyright-statement content-type="article-copyright">© 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-12-e029588.pdf"/>
              <abstract>
                <sec id="jah38582-sec-0001">
                  <title>Background</title>
                  <p>Frailty is rarely assessed in clinical trials of patients who receive dual antiplatelet therapy (DAPT) after percutaneous coronary intervention. This study investigated whether frailty defined using claims data is associated with outcomes following percutaneous coronary intervention, and if there is a differential association in patients receiving standard versus extended duration DAPT.</p>
                </sec>
                <sec id="jah38582-sec-0002">
                  <title>Methods and Results</title>
                  <p>Patients ≥65 years of age in the DAPT (Dual Antiplatelet Therapy) Study, a randomized trial comparing 30 versus 12 months of DAPT following percutaneous coronary intervention, had data linked to Medicare claims (n=1326), and a previously validated claims‐based index was used to define frailty. Net adverse clinical events, a composite of all‐cause mortality, myocardial infarction, stroke, and major bleeding, were compared between frail and nonfrail patients. Patients defined as frail using claims data (12.0% of the cohort) had higher incidence of net adverse clinical events (23.1%) compared with nonfrail patients (10.7%; <italic toggle="no">P</italic>&lt;0.001) at 18‐month follow‐up and increased risk after multivariable adjustment (adjusted hazard ratio [HR], 2.24 [95% CI, 1.38–3.63]). There were no differences in effects of extended duration DAPT on net adverse clinical events for frail (HR, 1.42 [95% CI, 0.73–2.75]) and nonfrail patients (HR, 1.18 [95% CI, 0.83–1.68]; interaction <italic toggle="no">P</italic>=0.61), although analyses were underpowered. Bleeding was highest among frail patients who received extended duration DAPT.</p>
                </sec>
                <sec id="jah38582-sec-0003">
                  <title>Conclusions</title>
                  <p>Among older patients in the DAPT Study, claims‐defined frailty was associated with higher net adverse clinical events. Effects of extended duration DAPT were not different for frail patients, although comparisons were underpowered. Further investigation of how frailty influences ischemic and bleeding risks with DAPT are warranted.</p>
                </sec>
                <sec id="jah38582-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT00977938.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jah38582-kwd-0001">administrative claims</kwd>
                <kwd id="jah38582-kwd-0002">bleeding</kwd>
                <kwd id="jah38582-kwd-0003">clinical trial</kwd>
                <kwd id="jah38582-kwd-0004">frailty</kwd>
                <kwd id="jah38582-kwd-0005">myocardial infarction</kwd>
                <kwd id="jah38582-kwd-0006">stroke</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Quality and Outcomes</kwd>
                <kwd>Chronic Ischemic Heart Disease</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Heart, Lung, and Blood Institute
</institution>
                      <institution-id institution-id-type="doi">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R01HL 136 708‐01</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="5"/>
                <page-count count="11"/>
                <word-count count="8075"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>18 July 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.2 mode:remove_FC converted:18.07.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="jah38582-ntgp-0001">
                <fn id="jah38582-note-0001">
                  <p>This article was sent to Amgad Mentias, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition.</p>
                </fn>
                <fn id="jah38582-note-0002">
                  <p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.029588" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.029588</ext-link>
</p>
                </fn>
                <fn id="jah38582-note-0003">
                  <p>For Sources of Funding and Disclosures, see page 9.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah38582-body-0001">
            <def-list list-content="abbreviations" id="jah38582-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term id="jah38582-li-0001">CFI</term>
                <def id="jah38582-li-0002">
                  <p>Claims‐Based Frailty Indicator</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38582-li-0003">DAPT</term>
                <def id="jah38582-li-0004">
                  <p>dual antiplatelet therapy</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38582-li-0005">FAC</term>
                <def id="jah38582-li-0006">
                  <p>frailty‐associated characteristic</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38582-li-0007">MACCE</term>
                <def id="jah38582-li-0008">
                  <p>major adverse cardiovascular and cerebrovascular events</p>
                </def>
              </def-item>
              <def-item>
                <term id="jah38582-li-0009">NACE</term>
                <def id="jah38582-li-0010">
                  <p>net adverse clinical events</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah38582-blkfxd-0001">
                <caption>
                  <title>Clinical Perspective</title>
                </caption>
                <sec id="jah38582-sec-0007">
                  <title>What Is New?</title>
                  <p>
                    <list list-type="bullet" id="jah38582-list-0001">
                      <list-item id="jah38582-li-0011">
                        <p>Frailty is rarely evaluated in clinical trials of patients with coronary artery disease but can potentially be assessed using administrative claims when frailty data are not otherwise available.</p>
                      </list-item>
                      <list-item id="jah38582-li-0012">
                        <p>In the DAPT (Dual Antiplatelet Therapy) Study, a randomized trial comparing 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention, patients with claims‐defined frailty had increased risk of adverse events.</p>
                      </list-item>
                      <list-item id="jah38582-li-0013">
                        <p>Frailty did not impact effects of 30 versus 12 months of dual antiplatelet therapy in patients following percutaneous coronary intervention in this analysis, although comparisons were underpowered.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
                <sec id="jah38582-sec-0008">
                  <title>What Are the Clinical Implications?</title>
                  <p>
                    <list list-type="bullet" id="jah38582-list-0002">
                      <list-item id="jah38582-li-0014">
                        <p>Further investigation of how frailty impacts ischemic and bleeding risks with antiplatelet therapy is warranted.</p>
                      </list-item>
                      <list-item id="jah38582-li-0015">
                        <p>This study supports supplemental use of administrative claims data in the context of cardiovascular clinical trials.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <p>Frailty is a state of increased vulnerability to stressors and decreased physiologic reserve,<xref rid="jah38582-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah38582-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="jah38582-bib-0003" ref-type="bibr"><sup>3</sup></xref> and is present in 1 out of 5 patients with coronary artery disease (CAD) who undergo percutaneous coronary intervention (PCI).<xref rid="jah38582-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="jah38582-bib-0005" ref-type="bibr"><sup>5</sup></xref> Frailty is strongly associated with adverse outcomes among patients with CAD, including up to a 4‐fold increased odds of all‐cause mortality.<xref rid="jah38582-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="jah38582-bib-0006" ref-type="bibr"><sup>6</sup></xref> Although frailty is widely acknowledged as clinically significant and is becoming more prevalent with the aging population, most clinical research studies including randomized trials do not measure or otherwise assess the impact of frailty on patient outcomes.<xref rid="jah38582-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="jah38582-bib-0008" ref-type="bibr"><sup>8</sup></xref> Additionally, there is no standardized method for assessing frailty, and physician assessment of frailty may not necessarily be associated with risk of adverse outcomes.<xref rid="jah38582-bib-0009" ref-type="bibr"><sup>9</sup></xref> Consequently, the generalizability of research findings to clinical management of frail patients with CAD remains uncertain.</p>
            <p>In particular, although prior studies have demonstrated that frailty is associated with increased short‐term risks of bleeding following PCI,<xref rid="jah38582-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah38582-bib-0011" ref-type="bibr"><sup>11</sup></xref> the long‐term risks of adverse outcomes in this population remain unknown. In addition, there is sparse evidence on how frailty impacts the balance of ischemic and bleeding risk in patients with CAD on dual antiplatelet therapy (DAPT) following PCI. Although frailty is associated with age, and older patients generally have increased mortality associated with bleeding and may therefore benefit from shorter duration of DAPT,<xref rid="jah38582-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="jah38582-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="jah38582-bib-0014" ref-type="bibr"><sup>14</sup></xref> the impact of this regimen specifically among frail patients has not been clearly demonstrated.</p>
            <p>One novel way to assess frailty when not otherwise evaluated is through use of administrative claims data, which can capture conditions associated with frailty through use of billing codes.<xref rid="jah38582-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jah38582-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jah38582-bib-0018" ref-type="bibr"><sup>18</sup></xref> Prior observational studies have used this approach,<xref rid="jah38582-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="jah38582-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jah38582-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="jah38582-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="jah38582-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="jah38582-bib-0024" ref-type="bibr"><sup>24</sup></xref> which may have additional value in the context of clinical trials. To assess this further, we used clinical trial data from the DAPT (Dual Antiplatelet Therapy) Study linked to Medicare claims to explore how frailty, defined based on a previously validated claims‐based frailty index, is related to long‐term adverse outcomes following PCI.<xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jah38582-bib-0025" ref-type="bibr"><sup>25</sup></xref> We also evaluated how claims‐defined frailty impacts treatment effects of 30 versus 12 months of DAPT following PCI.</p>
            <sec sec-type="methods" id="jah38582-sec-0009">
              <title>METHODS</title>
              <sec id="jah38582-sec-0010">
                <title>Overview of the <styled-content style="fixed-case" toggle="no">EXTEND‐DAPT</styled-content> Study</title>
                <p>This analysis was part of the EXTEND (Extending Trial‐Based Evaluations of Medical Therapies Using Novel Sources of Data) Study. An overview of the aims and methods of the EXTEND Study have been previously described.<xref rid="jah38582-bib-0026" ref-type="bibr"><sup>26</sup></xref> The EXTEND substudy, EXTEND‐DAPT, linked data from the DAPT Study to the American College of Cardiology's National Cardiovascular Data Registry (NCDR) CathPCI Registry and Medicare fee‐for‐service beneficiary claims.</p>
                <p>The DAPT Study was a randomized, multicenter, placebo‐controlled clinical trial of patients who underwent PCI and received DAPT consisting of aspirin and a P2Y12 inhibitor for 1 year (<ext-link xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> Identifier NCT00977938).<xref rid="jah38582-bib-0025" ref-type="bibr"><sup>25</sup></xref> At 1 year following PCI, patients without ischemic or bleeding events were randomized to either placebo (12 total months of DAPT) or continued thienopyridine for an additional 18 months (30 total months of DAPT). Patients were enrolled between August 13, 2009 and July 1, 2011. The Baim Institute for Clinical Research (formerly the Harvard Clinical Research Institute) conducted the trial, and the EXTEND Study has been approved by the institutional review board at Beth Israel Deaconess Medical Center with a waiver of informed consent. Data that support findings from this study are available from the corresponding author upon reasonable request.</p>
              </sec>
              <sec id="jah38582-sec-0011">
                <title>Study Population</title>
                <p>In this study we included all patients in the DAPT Study who were at least 65 years of age (the age of eligibility for Medicare), enrolled in fee‐for‐service Medicare insurance in the United States at the time of PCI, and could successfully be linked via the NCDR CathPCI Registry to the Centers for Medicare and Medicaid Services inpatient claims data.<xref rid="jah38582-bib-0027" ref-type="bibr"><sup>27</sup></xref> Deterministic algorithms based on age or date of birth, sex, PCI date, stent type, hospital discharge date, and hospital identifier were used to link DAPT Study data to the CathPCI Registry. These data were then linked to Medicare inpatient claims using direct identifiers available in the CathPCI Registry. Patients who could not be linked to the CathPCI Registry due to inexact matching variables or who were not found in Centers for Medicare and Medicaid Services fee‐for‐service claims data were excluded.</p>
                <p>The DAPT Study randomized 11 648 patients, and of these, 3908 were in the United States and ≥65 years of age. Data from 2558 of these patients were successfully linked to the CathPCI Registry, and 1336 were ultimately linked to Medicare inpatient claims; characteristics between linked and unlinked patients were generally similar, as previously reported.<xref rid="jah38582-bib-0028" ref-type="bibr"><sup>28</sup></xref> Ten patients were excluded because they were not enrolled in Medicare at the time of index PCI, and therefore did not have at least 12 months of inpatient claims data available to assess for frailty before the start of randomization. The final study cohort therefore consisted of 1326 patients (Figure <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S1</xref>). The primary reasons for inability to link Medicare‐eligible patients were being insured by Medicare Advantage (n=692) or lacking sufficient information to be identified in both data sources (n=530). All baseline characteristics other than claims‐defined frailty were obtained from information collected in the DAPT Study.</p>
              </sec>
              <sec id="jah38582-sec-0012">
                <title>Frailty Definitions</title>
                <p>In primary analyses for this study we defined frailty based on the Johns Hopkins Claims‐Based Frailty Indicator (CFI), a previously validated index that uses 21 variables available in claims data with <italic toggle="yes">International Classification of Diseases, Ninth Revision, Clinical Modification</italic> (<italic toggle="yes">ICD‐9‐CM</italic>) diagnosis codes.<xref rid="jah38582-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref> The Hopkins CFI is based on claims‐based variables that are predictive of the Fried definition of frailty, characterized by weight loss, exhaustion, weak grip strength, slow walk speed, and low physical activity.<xref rid="jah38582-bib-0029" ref-type="bibr"><sup>29</sup></xref> Frailty based on the Hopkins CFI has been significantly associated with adverse outcomes including incidence of falls, worsening mobility, acute hospitalization, and death.<xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="jah38582-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="jah38582-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="jah38582-bib-0021" ref-type="bibr"><sup>21</sup></xref> We specifically defined frailty using a Hopkins CFI cutoff of &gt;0.12, as suggested by the authors.<xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref>
</p>
                <p>We performed a separate exploratory analysis to assess frailty based on a cumulative deficit approach. In this analysis, frailty was based on total number of frailty‐associated characteristics (FACs) based on the Hopkins CFI as well as the Claims‐Based Frailty Index developed by Kim et al, another validated tool that predicts frailty based on cumulative deficits using survey‐reported functional limitations.<xref rid="jah38582-bib-0015" ref-type="bibr"><sup>15</sup></xref> This index includes&gt;90 variables from claims data, and is similarly predictive of poor outcomes including recurrent falls, impaired mobility, health care use, and death.<xref rid="jah38582-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jah38582-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="jah38582-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="jah38582-bib-0030" ref-type="bibr"><sup>30</sup></xref>
<italic toggle="yes">ICD‐9‐CM</italic> and <italic toggle="yes">Healthcare Common Procedure Coding System</italic> codes were grouped based on categories previously used for these 2 claims‐based indices. We only included variables from the Claims‐Based Frailty Index by Kim et al that had a ≥0.01 increase in index value based on the relevant lasso regression model, as directly reported by the authors.<xref rid="jah38582-bib-0015" ref-type="bibr"><sup>15</sup></xref> Incorporation of variables from both models resulted in 32 unique categories of claims‐based FACs, including neurologic and psychotic disorders, arthropathies, impaired mobility and falls, infections, and use of medical equipment (Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S1</xref>). Claims‐Based Frailty Index values by Kim et al were not assessed because we did not have access to outpatient claims, which are used in calculations of this index. Increasing frailty in this sensitivity analysis was based on having 0–3, 4–5, or ≥6 FACs, with ≥6 defined as frailty. These cutoffs were chosen to approximate the previously observed prevalence of frailty using the Fried definition in patients with coronary artery disease undergoing PCI.<xref rid="jah38582-bib-0005" ref-type="bibr"><sup>5</sup></xref>
</p>
              </sec>
              <sec id="jah38582-sec-0013">
                <title>Outcomes</title>
                <p>Outcomes for this study included death, myocardial infarction (MI), stroke, major bleeding, and net adverse clinical events (NACE). NACE were defined as a composite of the individual end points of all‐cause death, MI, stroke, and major bleeding. We also assessed major adverse cardiovascular and cerebrovascular events (a composite of death, MI, and stroke), because this was the primary outcome of the DAPT Study. All outcomes were assessed based on adjudication by the DAPT Study Clinical Events Committee. The trial used prespecified definitions of MI and stroke.<xref rid="jah38582-bib-0025" ref-type="bibr"><sup>25</sup></xref> Major bleeding was defined as any adjudicated event that met criteria for either moderate or severe bleeding based on GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries) classification, or type 3 or type 5 bleeding based on the Bleeding Academic Research Consortium (BARC) definitions.<xref rid="jah38582-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="jah38582-bib-0032" ref-type="bibr"><sup>32</sup></xref> To include minor bleeding events in our outcomes, we performed sensitivity analyses defining bleeding as BARC type 2, 3, or 5 bleeding. Cardiovascular and noncardiovascular death were evaluated as secondary end points. The study period for follow‐up was from time of randomization (12 months following PCI) to 18 months after randomization (30 months following PCI).</p>
                <p>To determine the association of frailty with adverse clinical events, cumulative incidence and adjusted risks of outcomes were analyzed across the entire cohort. To assess whether duration of DAPT impacted outcomes based on frailty status, we performed an exploratory analysis comparing groups randomized to 30 versus 12 months of DAPT stratified by frailty.</p>
              </sec>
              <sec id="jah38582-sec-0014">
                <title>Statistical Analysis</title>
                <p>Baseline characteristics are presented as percentages for categorical variables and means with SDs for continuous variables. Univariate comparisons of baseline characteristics were performed using the Fisher exact test for categorical variables and <italic toggle="yes">t</italic> test for continuous variables. Cumulative incidence rates of outcomes were determined in nonparametric survival analyses using Kaplan‐Meier estimates. To compare survivor functions of 30 versus 12 months of DAPT within each group, log‐rank tests were performed using outcomes observed up to 18 months following randomization. Cox regressions were used to determine hazard ratio (HR) with 95% CI for each outcome. Patients were censored at the last day of follow‐up or the end of the study period. For individual nondeath outcomes, patients were also censored at time of death, and we accounted for competing risk of death using a subdistribution hazard model based on the Fine‐Gray method.<xref rid="jah38582-bib-0033" ref-type="bibr"><sup>33</sup></xref>
</p>
                <p>To assess the association of frailty with adverse clinical events, cumulative incidence of outcomes was determined. Risks of clinical events were analyzed using Cox regression with adjustment for age, sex, total number of lifestyle‐related cardiovascular risk factors (diabetes, hypertension, smoking, or obesity), presence of an additional cardiovascular risk factor (any 1 of the following: prior PCI, prior coronary artery bypass graft, prior stroke or transient ischemic attack, prior MI, or MI at the time of index PCI), and DAPT study arm (30 or 12 months of DAPT). In sensitivity analyses using a cumulative deficit approach, patients with 0 to 3 FACs were used as the reference group, and adjusted analyses were repeated with FACs evaluated as a continuous variable.</p>
                <p>To assess the impact of frailty on treatment effects of 30 versus 12 months of DAPT after PCI, outcomes of randomized groups were analyzed using an intention‐to‐treat framework with stratification by the Hopkins CFI. Cumulative incidence and risks of outcomes were assessed separately for frail and nonfrail groups, and tests for interaction were performed using Cox regression. Similar sensitivity analyses were performed using frailty defined based on having ≥6 FACs. Adjustment was not performed in these analyses, because patient characteristics were similar between randomized groups. All analyses were conducted in SAS version 9.4 (SAS Institute, Cary, NC) using a 2‐tailed <italic toggle="yes">P</italic>&lt;0.05 to define significance.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah38582-sec-0015">
              <title>RESULTS</title>
              <sec id="jah38582-sec-0016">
                <title>Baseline Characteristics</title>
                <p>The mean age (SD) of this cohort was 71.9 (SD, 5.5) years, and 32.9% were women. Using a Hopkins CFI &gt;0.12, 159 (12.0%) patients were defined as frail, and 1167 (88.0%) were considered nonfrail. Baseline characteristics of patients stratified by frailty are shown in Table <xref rid="jah38582-tbl-0001" ref-type="table">1</xref>. Frail patients were older and more likely to be women and have prior history of stroke.</p>
                <table-wrap position="float" id="jah38582-tbl-0001" content-type="Table">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline Clinical Characteristics Based on Hopkins CFI in the Dual Antiplatelet Therapy Study</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" rowspan="1" colspan="1">Frail (CFI&gt;0.12; N=159)</th>
                        <th align="left" rowspan="1" colspan="1">Nonfrail (CFI≤0.12; N=1167)</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age, y, mean, SD</td>
                        <td align="left" rowspan="1" colspan="1">79.8, 5.5</td>
                        <td align="left" rowspan="1" colspan="1">70.8, 4.5</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Women</td>
                        <td align="left" rowspan="1" colspan="1">88 (55.3)</td>
                        <td align="left" rowspan="1" colspan="1">348 (29.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Non‐White race</td>
                        <td align="left" rowspan="1" colspan="1">20 (12.7)</td>
                        <td align="left" rowspan="1" colspan="1">67 (5.8)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hispanic/Latino ethnicity</td>
                        <td align="left" rowspan="1" colspan="1">6 (3.8)</td>
                        <td align="left" rowspan="1" colspan="1">27 (2.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.27</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI, mean, SD</td>
                        <td align="left" rowspan="1" colspan="1">28.3, 5.0</td>
                        <td align="left" rowspan="1" colspan="1">29.8, 5.3</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes</td>
                        <td align="left" rowspan="1" colspan="1">57 (35.8)</td>
                        <td align="left" rowspan="1" colspan="1">384 (33.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.47</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">142 (89.9)</td>
                        <td align="left" rowspan="1" colspan="1">985 (84.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.08</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Current or recent smoking</td>
                        <td align="left" rowspan="1" colspan="1">6 (3.8)</td>
                        <td align="left" rowspan="1" colspan="1">142 (12.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke/TIA</td>
                        <td align="left" rowspan="1" colspan="1">21 (13.2)</td>
                        <td align="left" rowspan="1" colspan="1">51 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Congestive heart failure</td>
                        <td align="left" rowspan="1" colspan="1">25 (15.8)</td>
                        <td align="left" rowspan="1" colspan="1">60 (5.2)</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Peripheral arterial disease</td>
                        <td align="left" rowspan="1" colspan="1">24 (15.4)</td>
                        <td align="left" rowspan="1" colspan="1">111 (9.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.03</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of major bleeding</td>
                        <td align="left" rowspan="1" colspan="1">1 (0.6)</td>
                        <td align="left" rowspan="1" colspan="1">12 (1.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior PCI</td>
                        <td align="left" rowspan="1" colspan="1">53 (33.5)</td>
                        <td align="left" rowspan="1" colspan="1">409 (35.3)</td>
                        <td align="left" rowspan="1" colspan="1">0.67</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior CABG</td>
                        <td align="left" rowspan="1" colspan="1">21 (13.2)</td>
                        <td align="left" rowspan="1" colspan="1">198 (17.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.23</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">31 (20.1)</td>
                        <td align="left" rowspan="1" colspan="1">239 (21.0)</td>
                        <td align="left" rowspan="1" colspan="1">0.80</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Atrial fibrillation</td>
                        <td align="left" rowspan="1" colspan="1">10 (6.3)</td>
                        <td align="left" rowspan="1" colspan="1">53 (4.6)</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" rowspan="1">Index PCI indication</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">STEMI</td>
                        <td align="left" rowspan="1" colspan="1">2 (1.3)</td>
                        <td align="left" rowspan="1" colspan="1">51 (4.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.06</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">NSTEMI</td>
                        <td align="left" rowspan="1" colspan="1">24 (15.1)</td>
                        <td align="left" rowspan="1" colspan="1">121 (10.4)</td>
                        <td align="left" rowspan="1" colspan="1">0.07</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Unstable angina</td>
                        <td align="left" rowspan="1" colspan="1">27 (17.0)</td>
                        <td align="left" rowspan="1" colspan="1">174 (14.9)</td>
                        <td align="left" rowspan="1" colspan="1">0.49</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Stable angina</td>
                        <td align="left" rowspan="1" colspan="1">65 (40.9)</td>
                        <td align="left" rowspan="1" colspan="1">531 (45.5)</td>
                        <td align="left" rowspan="1" colspan="1">0.27</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38582-ntgp-0002">
                    <fn id="jah38582-note-0004">
                      <p>BMI indicates body mass index; CABG, coronary artery bypass graft; CFI, Claims‐Based Frailty Indicator; NSTEMI, non–ST‐segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST‐segment–elevation myocardial infarction; and TIA, transient ischemic attack.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38582-sec-0017">
                <title>Adverse Outcomes Based on Claims‐Defined Frailty</title>
                <p>After 18 months of follow‐up, patients with frailty based on the Hopkins CFI had higher cumulative incidence of NACE (23.1%) compared with patients without frailty (10.7%; log‐rank <italic toggle="yes">P</italic>&lt;0.001; Figure <xref rid="jah38582-fig-0001" ref-type="fig">1</xref>). Patients with frailty also had higher incidence of major adverse cardiovascular and cerebrovascular events, all‐cause death, MI, and major bleeding (Table <xref rid="jah38582-tbl-0002" ref-type="table">2</xref>). In adjusted analyses, patients with frailty had higher risk of these outcomes compared with nonfrail patients (Table <xref rid="jah38582-tbl-0003" ref-type="table">3</xref>). Consistent with the primary analyses, results from adjusted analyses evaluating Hopkins CFI as a continuous variable showed that increasing CFI was associated with increased risk of most outcomes including NACE and major adverse cardiovascular and cerebrovascular events (Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S2</xref>). When minor bleeding was included in the bleeding end point, patients with frailty had higher incidence and adjusted risks of bleeding and NACE (Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S3</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S4</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah38582-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <title>Cumulative incidence of net adverse events based on claims‐based frailty in the EXTEND‐DAPT study.</title>
                    <p>All outcomes were assessed from time of randomization (12 months following PCI) to 18 months post‐randomization (30 months following PCI) in the DAPT Study. NACE was a composite outcome inclusive of all‐cause mortality, MI, stroke, and major bleeding. CFI indicates Claims‐Based Frailty Indicator; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NACE, net adverse clinical events; and PCI, percutaneous coronary intervention.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e029588-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="jah38582-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Cumulative Incidence of Adverse Outcomes Based on the Hopkins CFI</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Outcome</th>
                        <th align="left" rowspan="1" colspan="1">Frail (CFI &gt;0.12; N=159)</th>
                        <th align="left" rowspan="1" colspan="1">Non‐Frail (CFI ≤0.12; N=1167)</th>
                        <th align="left" rowspan="1" colspan="1">Log‐rank <italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NACE</td>
                        <td align="left" rowspan="1" colspan="1">23.1</td>
                        <td align="left" rowspan="1" colspan="1">10.7</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MACCE</td>
                        <td align="left" rowspan="1" colspan="1">14.1</td>
                        <td align="left" rowspan="1" colspan="1">5.7</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Death</td>
                        <td align="left" rowspan="1" colspan="1">6.5</td>
                        <td align="left" rowspan="1" colspan="1">2.0</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">0.9</td>
                        <td align="left" rowspan="1" colspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Noncardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">4.6</td>
                        <td align="left" rowspan="1" colspan="1">1.2</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MI</td>
                        <td align="left" rowspan="1" colspan="1">6.6</td>
                        <td align="left" rowspan="1" colspan="1">3.4</td>
                        <td align="left" rowspan="1" colspan="1">0.041</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="left" rowspan="1" colspan="1">3.3</td>
                        <td align="left" rowspan="1" colspan="1">1.2</td>
                        <td align="left" rowspan="1" colspan="1">0.029</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Major bleeding</td>
                        <td align="left" rowspan="1" colspan="1">11.1</td>
                        <td align="left" rowspan="1" colspan="1">3.4</td>
                        <td align="left" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38582-ntgp-0003">
                    <fn id="jah38582-note-0005">
                      <p>All outcomes were assessed from time of randomization (12 months following percutaneous coronary intervention) to 18 months after randomization (30 months following percutaneous coronary intervention) in the Dual Antiplatelet Therapy Study. NACE was a composite outcome inclusive of all‐cause mortality, MI, stroke, and major bleeding, and MACCE was a composite of all‐cause mortality, MI, and stroke. CFI indicates Claims‐Based Frailty Indicator; MACCE, major adverse cardiovascular or cerebrovascular events; MI, myocardial infarction; and NACE, net adverse clinical events.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="jah38582-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Adjusted Risks of Adverse Outcomes for Patients With Frailty Based on Hopkins CFI &gt;0.12</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Outcome</th>
                        <th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI) (reference: CFI ≤0.12)</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NACE</td>
                        <td align="left" rowspan="1" colspan="1">2.24 (1.38–3.63)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MACCE</td>
                        <td align="left" rowspan="1" colspan="1">2.93 (1.54–5.57)</td>
                        <td align="left" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Death</td>
                        <td align="left" rowspan="1" colspan="1">3.05 (1.10–8.47)</td>
                        <td align="left" rowspan="1" colspan="1">0.032</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.73 (0.32–9.49)</td>
                        <td align="left" rowspan="1" colspan="1">0.529</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Noncardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">4.39 (1.22–15.75)</td>
                        <td align="left" rowspan="1" colspan="1">0.023</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">2.60 (1.06–6.37)</td>
                        <td align="left" rowspan="1" colspan="1">0.038</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="left" rowspan="1" colspan="1">3.27 (0.81–13.14)</td>
                        <td align="left" rowspan="1" colspan="1">0.095</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Major Bleeding</td>
                        <td align="left" rowspan="1" colspan="1">2.43 (1.11–5.31)</td>
                        <td align="left" rowspan="1" colspan="1">0.026</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38582-ntgp-0004">
                    <fn id="jah38582-note-0006">
                      <p>Outcomes were adjusted for age, sex, total number of lifestyle‐related cardiovascular risk factors (diabetes, hypertension, smoking, or obesity), presence of an additional cardiovascular risk factor (any 1 of the following: prior percutaneous coronary intervention, prior coronary artery bypass graft, prior stroke or transient ischemic attack, prior myocardial infarction, or myocardial infarction at the time of index percutaneous coronary intervention), and Dual Antiplatelet Therapy Study arm (30 or 12 months of dual antiplatelet therapy). CFI indicates Claims‐Based Frailty Indicator; HR, hazard ratio; MACCE, major adverse cardiovascular or cerebrovascular events; and NACE, net adverse clinical events.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="jah38582-sec-0018">
                <title>Treatment Effects of Extended Duration DAPT Based on Claims‐Defined Frailty</title>
                <p>Baseline characteristics of subgroups based on DAPT duration and frailty defined by the Hopkins CFI were similar (Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S5</xref>). In comparisons of patients by randomized treatment arm, the cumulative incidence of NACE after PCI was 11.5% with 30 months of DAPT and 9.9% with 12 months of DAPT among nonfrail patients (HR, 1.18 [95% CI, 0.83–1.68]; <italic toggle="yes">P</italic>=0.36). Among patients with frailty, the cumulative incidence of NACE was 26.7% with 30 months of DAPT and 19.5% with 12 months of DAPT (HR, 1.42 [95% CI, 0.73–2.75]; <italic toggle="yes">P</italic>=0.30) (interaction <italic toggle="yes">P</italic>=0.61; Figure <xref rid="jah38582-fig-0002" ref-type="fig">2</xref>; Tables <xref rid="jah38582-tbl-0004" ref-type="table">4</xref> and <xref rid="jah38582-tbl-0005" ref-type="table">5</xref>). There were no statistically significant differences in incidence of any of the individual end points with 30 versus 12 months of DAPT when stratified by frailty status, though both nonfrail and frail patients had numerically higher incidence of major bleeding with extended DAPT (Tables <xref rid="jah38582-tbl-0004" ref-type="table">4</xref> and <xref rid="jah38582-tbl-0005" ref-type="table">5</xref>).</p>
                <fig position="float" fig-type="Figure" id="jah38582-fig-0002">
                  <label>Figure 2</label>
                  <caption>
                    <title>Cumulative incidence of net adverse events based on claims‐based frailty and duration of DAPT in the EXTEND‐DAPT study.</title>
                    <p>All outcomes were assessed from time of randomization (12 months following PCI) to 18 months post‐randomization (30 months following PCI) in the DAPT Study. NACE was a composite outcome inclusive of all‐cause mortality, MI, stroke, and major bleeding. CFI indicates Claims‐Based Frailty Indicator; DAPT, dual antiplatelet therapy; MI, myocardial infarction; NACE, net adverse clinical events; and PCI, percutaneous coronary intervention.</p>
                  </caption>
                  <graphic xlink:href="JAH3-12-e029588-g002" position="anchor" id="jats-graphic-3"/>
                </fig>
                <table-wrap position="float" id="jah38582-tbl-0004" content-type="Table">
                  <label>Table 4</label>
                  <caption>
                    <p>Incidence of Adverse Outcomes by Dual Antiplatelet Therapy Duration and CFI</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Outcome</th>
                        <th align="left" rowspan="1" colspan="1">30 Mo nonfrail CFI ≤0.12 (n=571)</th>
                        <th align="left" rowspan="1" colspan="1">12 Mo nonfrail CFI ≤0.12 (n=596)</th>
                        <th align="left" rowspan="1" colspan="1">Log‐rank <italic toggle="yes">P</italic> value</th>
                        <th align="left" rowspan="1" colspan="1">30 Mo frail CFI &gt;0.12 (n=81)</th>
                        <th align="left" rowspan="1" colspan="1">12 Mo frail CFI &gt;0.12 (n=78)</th>
                        <th align="left" rowspan="1" colspan="1">Log‐rank <italic toggle="yes">P</italic> Value</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NACE</td>
                        <td align="left" rowspan="1" colspan="1">11.5</td>
                        <td align="left" rowspan="1" colspan="1">9.9</td>
                        <td align="left" rowspan="1" colspan="1">0.36</td>
                        <td align="left" rowspan="1" colspan="1">26.7</td>
                        <td align="left" rowspan="1" colspan="1">19.5</td>
                        <td align="left" rowspan="1" colspan="1">0.30</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MACCE</td>
                        <td align="left" rowspan="1" colspan="1">5.1</td>
                        <td align="left" rowspan="1" colspan="1">6.3</td>
                        <td align="left" rowspan="1" colspan="1">0.32</td>
                        <td align="left" rowspan="1" colspan="1">15.2</td>
                        <td align="left" rowspan="1" colspan="1">13.0</td>
                        <td align="left" rowspan="1" colspan="1">0.69</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Death</td>
                        <td align="left" rowspan="1" colspan="1">2.5</td>
                        <td align="left" rowspan="1" colspan="1">1.5</td>
                        <td align="left" rowspan="1" colspan="1">0.25</td>
                        <td align="left" rowspan="1" colspan="1">7.6</td>
                        <td align="left" rowspan="1" colspan="1">5.2</td>
                        <td align="left" rowspan="1" colspan="1">0.54</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.1</td>
                        <td align="left" rowspan="1" colspan="1">0.7</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                        <td align="left" rowspan="1" colspan="1">1.3</td>
                        <td align="left" rowspan="1" colspan="1">2.6</td>
                        <td align="left" rowspan="1" colspan="1">0.55</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Noncardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.5</td>
                        <td align="left" rowspan="1" colspan="1">0.9</td>
                        <td align="left" rowspan="1" colspan="1">0.27</td>
                        <td align="left" rowspan="1" colspan="1">6.5</td>
                        <td align="left" rowspan="1" colspan="1">2.7</td>
                        <td align="left" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">2.9</td>
                        <td align="left" rowspan="1" colspan="1">3.8</td>
                        <td align="left" rowspan="1" colspan="1">0.39</td>
                        <td align="left" rowspan="1" colspan="1">7.7</td>
                        <td align="left" rowspan="1" colspan="1">5.3</td>
                        <td align="left" rowspan="1" colspan="1">0.51</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="left" rowspan="1" colspan="1">1.1</td>
                        <td align="left" rowspan="1" colspan="1">1.2</td>
                        <td align="left" rowspan="1" colspan="1">0.84</td>
                        <td align="left" rowspan="1" colspan="1">2.7</td>
                        <td align="left" rowspan="1" colspan="1">3.9</td>
                        <td align="left" rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Major bleeding</td>
                        <td align="left" rowspan="1" colspan="1">4.2</td>
                        <td align="left" rowspan="1" colspan="1">2.6</td>
                        <td align="left" rowspan="1" colspan="1">0.15</td>
                        <td align="left" rowspan="1" colspan="1">14.4</td>
                        <td align="left" rowspan="1" colspan="1">7.8</td>
                        <td align="left" rowspan="1" colspan="1">0.24</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38582-ntgp-0005">
                    <fn id="jah38582-note-0007">
                      <p>CFI indicates Claims‐Based Frailty Indicator; MACCE, major adverse cardiovascular or cerebrovascular events; and NACE, net adverse clinical events.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="jah38582-tbl-0005" content-type="Table">
                  <label>Table 5</label>
                  <caption>
                    <p>Risks of Adverse Outcomes for 30 Versus 12 Months of Dual Antiplatelet Therapy Stratified by Claims‐Based Frailty</p>
                  </caption>
                  <table frame="hsides" rules="all">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="1" colspan="1">Outcome</th>
                        <th align="left" rowspan="1" colspan="1">30 vs 12 Mo nonfrail CFI ≤0.12, HR (95% CI)</th>
                        <th align="left" rowspan="1" colspan="1">30 vs 12 Mo frail CFI &gt;0.12, HR (95% CI)</th>
                        <th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value for interaction</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NACE</td>
                        <td align="left" rowspan="1" colspan="1">1.18 (0.83–1.68)</td>
                        <td align="left" rowspan="1" colspan="1">1.42 (0.73–2.75)</td>
                        <td align="left" rowspan="1" colspan="1">0.61</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">MACCE</td>
                        <td align="left" rowspan="1" colspan="1">0.78 (0.48–1.27)</td>
                        <td align="left" rowspan="1" colspan="1">1.19 (0.51–2.75)</td>
                        <td align="left" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Death</td>
                        <td align="left" rowspan="1" colspan="1">1.63 (0.71–3.76)</td>
                        <td align="left" rowspan="1" colspan="1">1.48 (0.42–5.23)</td>
                        <td align="left" rowspan="1" colspan="1">0.90</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Cardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.57 (0.44–5.56)</td>
                        <td align="left" rowspan="1" colspan="1">0.49 (0.05–5.42)</td>
                        <td align="left" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" rowspan="1" colspan="1">Noncardiovascular</td>
                        <td align="left" rowspan="1" colspan="1">1.68 (0.55–5.12)</td>
                        <td align="left" rowspan="1" colspan="1">2.46 (0.48–12.67)</td>
                        <td align="left" rowspan="1" colspan="1">0.70</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Myocardial infarction</td>
                        <td align="left" rowspan="1" colspan="1">0.75 (0.40–1.43)</td>
                        <td align="left" rowspan="1" colspan="1">1.52 (0.43–5.39)</td>
                        <td align="left" rowspan="1" colspan="1">0.33</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke</td>
                        <td align="left" rowspan="1" colspan="1">0.89 (0.30–2.66)</td>
                        <td align="left" rowspan="1" colspan="1">0.65 (0.11–3.89)</td>
                        <td align="left" rowspan="1" colspan="1">0.76</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Major bleeding</td>
                        <td align="left" rowspan="1" colspan="1">1.61 (0.84–3.08)</td>
                        <td align="left" rowspan="1" colspan="1">1.81 (0.67–4.89)</td>
                        <td align="left" rowspan="1" colspan="1">0.83</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="jah38582-ntgp-0006">
                    <fn id="jah38582-note-0008">
                      <p>CFI indicates Claims‐Based Frailty Indicator; HR, hazard ratio; MACCE, major adverse cardiovascular or cerebrovascular events; and NACE, net adverse clinical events.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>When minor bleeding was included, patients with extended duration DAPT had a similar relative effect on the incidence of bleeding for patients with CFI &lt;0.12 (8.1% versus 4.0%, <italic toggle="yes">P</italic>=0.003; HR, 2.09 [95% CI, 1.26–3.45]) and CFI ≥0.12 (20.7% versus 11.8%, <italic toggle="yes">P</italic>=0.16; HR, 1.77 [95% CI 0.78–4.02]; interaction <italic toggle="yes">P</italic>=0.75; Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S6</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S7</xref>). Absolute risk differences for all outcomes are shown in Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S8</xref>.</p>
              </sec>
              <sec id="jah38582-sec-0019">
                <title>Sensitivity Analyses Using Frailty‐Associated Characteristics in Claims Data</title>
                <p>In sensitivity analyses based on a cumulative deficit approach for frailty, a total of 761 (57.4%) patients had 0 to 3 FACs, 326 (24.6%) had 4 to 5 FACs, and 239 (18.0%) had ≥6 FACs. The overall distribution of FACs is shown in Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S9</xref>, and baseline characteristics are shown in Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S10</xref>. Aside from demographic details and traditional comorbidities, the most common FACs identified in claims data were arthropathies/musculoskeletal disorders (32.0%), neurotic/personality/other nonpsychotic mental disorders (15.8%), and other diseases of the urinary system (13.7%; Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S11</xref>).</p>
                <p>Consistent with the primary analyses, patients with frailty based on having ≥6 FACs had increased incidence of adverse outcomes in unadjusted analyses and after multivariable adjustment (Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S12</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S13</xref>; Figure <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S2</xref>). Evaluating FACs as a continuous variable showed that increasing number of FACs was associated with increased risk of most outcomes including NACE and bleeding (Table <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S14</xref>). When minor bleeding was included in the bleeding end point, patients with greater number of FACs similarly had higher incidence and adjusted risk of bleeding and NACE (Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S15</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S16</xref>).</p>
                <p>There were no statistically significant differences in incidence of any of the individual end points with 30 versus 12 months of DAPT when stratified by frailty status based on ≥6 FACs (Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S17</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S18</xref>; Figure <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S3</xref>), and findings for NACE and bleeding did not change when minor bleeding was included (Tables <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S19</xref> and <xref rid="jah38582-supitem-0001" ref-type="supplementary-material">S20</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah38582-sec-0020">
              <title>DISCUSSION</title>
              <p>In this study we showed that frailty defined by a previously validated claims‐based index was associated with NACE in a subgroup of older patients who underwent PCI and were enrolled in the DAPT Study. We found numerical increases in NACE with longer DAPT duration among more frail patients; however, these analyses were underpowered, and differences were not statistically significant. Findings from this study support further inquiry into how frailty impacts ischemic and bleeding risks with antiplatelet therapies for CAD, and also support supplemental use of administrative claims data in the context of cardiovascular clinical trials.</p>
              <p>Though administrative claims data have been widely used for observational studies,<xref rid="jah38582-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="jah38582-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="jah38582-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="jah38582-bib-0037" ref-type="bibr"><sup>37</sup></xref> they have not been frequently used in studies of randomized clinical trials. However, inclusion of claims in data collection for clinical trials may provide several unique benefits, such as more efficient end point ascertainment, lower costs, and longer‐term follow‐up.<xref rid="jah38582-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="jah38582-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="jah38582-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="jah38582-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="jah38582-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="jah38582-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="jah38582-bib-0041" ref-type="bibr"><sup>41</sup></xref> Claims data may also provide important clinical information not otherwise assessed in clinical trial data. Frailty is rarely measured or included in clinical trials, although it is a strong predictor of adverse outcomes.<xref rid="jah38582-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="jah38582-bib-0007" ref-type="bibr"><sup>7</sup></xref> Consequently, the generalizability of most clinical trial findings to frail patients is uncertain. However, novel measures of frailty have been developed using claims data<xref rid="jah38582-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="jah38582-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="jah38582-bib-0017" ref-type="bibr"><sup>17</sup></xref> and may have usefulness when included in clinical trials.<xref rid="jah38582-bib-0042" ref-type="bibr"><sup>42</sup></xref>
</p>
              <p>In this post hoc analysis of the DAPT Study, we were able to use claims data to identify a subgroup of clinical trial patients with greater frailty and show that patients with CAD and frailty had increased risk of NACE in long‐term follow‐up. However, our cohort was smaller than the overall DAPT Study because only a minority were in the United States and had inpatient claims data available with Medicare fee‐for‐service insurance. Not all US patients had PCI performed at a hospital that participated in the CathPCI Registry, and outpatient and observation Medicare claims data were also not available, which likely contributed to the smaller size of our cohort. As a result, there was low power to detect significant differences in treatment effects between frail and nonfrail patients, although adverse outcomes were generally increased among frail patients. These findings appear to be consistent with prior studies showing that patients with CAD and frailty based on other measures such as the Fried frailty phenotype are at increased risk of adverse events, including death,<xref rid="jah38582-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="jah38582-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="jah38582-bib-0045" ref-type="bibr"><sup>45</sup></xref> as well as MI, stroke, and bleeding.<xref rid="jah38582-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="jah38582-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah38582-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah38582-bib-0046" ref-type="bibr"><sup>46</sup></xref>, <xref rid="jah38582-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="jah38582-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="jah38582-bib-0049" ref-type="bibr"><sup>49</sup></xref>, <xref rid="jah38582-bib-0050" ref-type="bibr"><sup>50</sup></xref>
</p>
              <p>We add to the evidence available from these prior observational studies by demonstrating that claims data can potentially be used to approximate frailty when it is not otherwise prospectively measured in a clinical trial. Ideally, clinical trials would directly measure frailty at baseline using validated in‐person assessment tools, and investigators should carefully consider this in early stages of trial design. However, due to reasons such as inadequate time, the labor‐intensive nature of such assessments, prohibitive cost, or lack of prioritization by investigators, this is rarely done. Frailty assessments based on previously validated claims‐based indices may have prognostic value similar to other methods of measuring frailty.<xref rid="jah38582-bib-0042" ref-type="bibr"><sup>42</sup></xref> Data from administrative claims have particular advantages for use in clinical trials given that they are ubiquitously used in health care, are often less expensive than other data collection methods, and can be easily analyzed retrospectively. In addition, claims data with long‐term follow‐up, such as in Medicare, allow for longitudinal assessment of outcomes associated with frailty. Claims data are already acknowledged as an important component of national efforts to expand use of real‐world evidence.<xref rid="jah38582-bib-0051" ref-type="bibr"><sup>51</sup></xref> Further investigation on the use of claims data within clinical trials to assess frailty and perhaps other unmeasured variables of interest is therefore warranted. Greater use of claims data would require more regular linkage with clinical trial data, as has occurred retrospectively in this study and prospectively within several pragmatic trials.<xref rid="jah38582-bib-0052" ref-type="bibr"><sup>52</sup></xref>, <xref rid="jah38582-bib-0053" ref-type="bibr"><sup>53</sup></xref>
</p>
              <p>In randomized comparisons in our study, we did not find statistically significant differences in treatment effects of extended duration DAPT after PCI for frail and nonfrail patients. Even so, we did find that frail patients had a numerically 37% higher incidence of NACE and 85% higher incidence of major bleeding with 30 months of DAPT, reinforcing the anticipated low power of our analysis. Importantly, decisions related to antiplatelet therapy following PCI often depend on balancing the protective benefits of therapy for reducing ischemic events with potential bleeding risks. Prior observational evidence has shown that frailty is associated with higher risk of bleeding related to cardiac catheterization and other causes of major bleeding within 30 days of acute coronary syndrome,<xref rid="jah38582-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="jah38582-bib-0011" ref-type="bibr"><sup>11</sup></xref> but there is little evidence from clinical trials on how frailty impacts bleeding risks of antiplatelet therapies. In the overall DAPT Study, increasing age was a significant predictor of bleeding but not ischemic events.<xref rid="jah38582-bib-0014" ref-type="bibr"><sup>14</sup></xref> Additional data from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Trial showed that long‐term clopidogrel use more than doubled the risk of bleeding for patients ≥75 years of age compared with placebo.<xref rid="jah38582-bib-0054" ref-type="bibr"><sup>54</sup></xref>
</p>
              <p>Some of the bleeding risk associated with age may be related to frailty‐associated mechanisms including underlying inflammatory dysregulation, decreased thrombus stability, decreased platelet turnover, variations in pharmacokinetics due to decreased muscle mass, and increased vascular fragility.<xref rid="jah38582-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="jah38582-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="jah38582-bib-0055" ref-type="bibr"><sup>55</sup></xref> However, clinical trials of antiplatelets for patients with CAD tend to exclude frail patients and do not specifically measure frailty or assess its effect on bleeding and other outcomes. When considered with a prior EXTEND‐DAPT study that suggested attenuated benefits and greater harms with DAPT in contemporary real‐world populations,<xref rid="jah38582-bib-0056" ref-type="bibr"><sup>56</sup></xref> our study may further bring into question the use of extended duration DAPT in frail patients. Our work also emphasizes the need to assess frailty more routinely in clinical trials of patients with CAD. Importantly, frailty is not necessarily equivalent to advanced age, and additional tools are needed to assess frailty more accurately in clinical practice and trial settings. Examples of these include validated measures such as the Fried phenotype and Clinical Frailty Scale.<xref rid="jah38582-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="jah38582-bib-0057" ref-type="bibr"><sup>57</sup></xref> Development of a frailty score specific to older patients with CAD could also help predict outcomes and guide medication decisions related to DAPT following PCI.</p>
              <p>Our study has several limitations. We indirectly assessed frailty based on <italic toggle="yes">ICD‐9‐CM</italic> diagnosis codes in claims data rather than more widely used measures such as the Fried phenotype. However, the validated index we used was based on the Fried definition and has been consistently associated with worse clinical outcomes in prior studies. Furthermore, a claims‐based definition of frailty using a cumulative deficit approach was also used and demonstrated similar findings. Even so, frailty encompasses important domains that include psychosocial and nutritional factors, which could not be directly assessed in our data.<xref rid="jah38582-bib-0003" ref-type="bibr"><sup>3</sup></xref> For example, lack of independence at home is a marker of frailty and is associated with increased mortality after PCI,<xref rid="jah38582-bib-0058" ref-type="bibr"><sup>58</sup></xref> but is not fully captured in claims data. Another limitation is that only inpatient <italic toggle="yes">ICD‐9‐CM</italic> diagnosis codes from Medicare fee‐for‐service beneficiaries were available and used during the time period of the trial. Further evidence is therefore needed to determine how frailty and associated outcomes can be assessed with the currently used inpatient and outpatient <italic toggle="yes">ICD‐10</italic> codes, in populations enrolled in Medicare Advantage, and in those &lt;65 years of age. As previously noted, our cohort was a selected subgroup of patients with Medicare in the DAPT Study, and the number of patients defined as frail was relatively small. Therefore, our analyses were likely underpowered to detect statistically significant differences, particularly for outcomes with few events, and all randomized comparisons should be considered exploratory. The size of our cohort also limited the number of variables we could include in adjusted analyses. Lastly, our study was limited to patients who met inclusion and exclusion criteria for the DAPT Study. Therefore, our findings are not necessarily generalizable to the larger population or to frail patients who would have likely been excluded from trial participation.</p>
            </sec>
            <sec sec-type="conclusions" id="jah38582-sec-0021">
              <title>CONCLUSIONS</title>
              <p>In this study we found that frailty based on claims data was associated with higher net adverse clinical events in a subgroup of older patients enrolled in the DAPT Study. We had insufficient power to detect differences in the treatment effect for extended duration DAPT following PCI for frail and nonfrail patients, although our findings suggest that further investigation is warranted. Claims data may be useful for augmenting risk prediction and assessing heterogeneity of treatment effects in cardiovascular clinical trials.</p>
            </sec>
            <sec id="jah38582-sec-0023">
              <title>Sources of Funding</title>
              <p>This research was funded by the National Heart, Lung, and Blood Institute (grant 1R01HL 136 708‐01, Dr Yeh).</p>
            </sec>
            <sec id="jah38582-sec-0024">
              <title>Disclosures</title>
              <p>Dr Faridi receives research funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL161424), outside the scope of the current work. Dr Strom is funded by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (1K23HL144907). Dr Strom also reports research funding from Edwards Lifesciences, Ultromics, Anumana, and HeartSciences; consulting for Bracco Diagnostics; and speaker honoraria from Northwest Imaging Forums, outside of the current work. Dr Kundi is funded by a grant from the Scientific and Technological Research Council of Turkey (3501;120S422), outside the scope of the current work. Dr Curtis has a contract with the American College of Cardiology for his role as Senior Medical Officer, NCDR, and receives salary support from the American College of Cardiology, NCDR. He holds equity interest in Medtronic. Dr Shen is an employee of Biogen. Dr Secemsky receives research funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL150290), Food and Drug Administration, Harvard Medical School's Shore Faculty Development Award, AstraZeneca, BD, Boston Scientific, Cook, CSI, Laminate Medical, Medtronic, and Philips. He also is a consultant and speaker for Abbott, Bayer, BD, Boston Scientific, Cook, CSI, Endovascular Engineering, Inari, Janssen, Medtronic, Philips, and VentureMed. Dr Yeh receives consulting fees and research funding from Abbott Vascular, Boston Scientific, and Medtronic; research funding from BD Bard, Cook, and Philips; and consulting fees from Elixir Medical, Shockwave, and Zoll. The remaining authors have no disclosures to report.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="jah38582-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>Tables S1–S20</p>
                  <p>Figures S1–S3</p>
                </caption>
                <media xlink:href="JAH3-12-e029588-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="jah38582-sec-0022">
              <title>Acknowledgments</title>
              <p>The authors would like to acknowledge the participation of the American College of Cardiology in this study. This study used data provided by the American College of Cardiology's NCDR. The views expressed represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies identified at <ext-link xlink:href="http://cvquality.acc.org/NCDR" ext-link-type="uri">CVQuality.ACC.org/NCDR</ext-link>. All authors have reviewed and approved the article being submitted. Dr Faridi contributed to the conception and design of the study, the supervision, data acquisition, analysis and interpretation, the article drafting, and the critical revision of the article. Dr Strom contributed to the conception and design of the study, analysis and interpretation, the article drafting, and the critical revision of the article. Dr Kundi contributed to the conception and design of the study, the article drafting, and the critical revision of the article. Dr Butala contributed to the analysis and interpretation, the article drafting, and the critical revision of the article. Dr Curtis contributed to the analysis and interpretation, the article drafting, and the critical revision of the article. Q. Gao contributed to the data acquisition, analysis and interpretation, the article drafting, and the critical revision of the article. Y. Song contributed to the data acquisition, analysis and interpretation, the article drafting, and the critical revision of the article. L. Zheng contributed to the data acquisition, analysis and interpretation, the article drafting, and the critical revision of the article. Dr Tamez contributed to the analysis and interpretation, the article drafting, and the critical revision of the article. Dr Shen contributed to the conception and design of the study, analysis and interpretation, the article drafting, and the critical revision of the article. Dr Secemsky contributed to the analysis and interpretation, the article drafting, and the critical revision of the article. Dr Yeh contributed to the conception and design of the study, the supervision, data acquisition, analysis and interpretation, the article drafting, and the critical revision of the article.</p>
            </ack>
            <ref-list content-type="cited-references" id="jah38582-bibl-0001">
              <title>References</title>
              <ref id="jah38582-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0001"><string-name><surname>Bergman</surname><given-names>H</given-names></string-name>, <string-name><surname>Ferrucci</surname><given-names>L</given-names></string-name>, <string-name><surname>Guralnik</surname><given-names>J</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DB</given-names></string-name>, <string-name><surname>Hummel</surname><given-names>S</given-names></string-name>, <string-name><surname>Karunananthan</surname><given-names>S</given-names></string-name>, <string-name><surname>Wolfson</surname><given-names>C</given-names></string-name>. <article-title>Frailty: an emerging research and clinical paradigm—issues and controversies</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2007</year>;<volume>62</volume>:<fpage>731</fpage>–<lpage>737</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/62.7.731</pub-id>
<pub-id pub-id-type="pmid">17634320</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0002"><string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Mack</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Maurer</surname><given-names>MS</given-names></string-name>, <string-name><surname>Green</surname><given-names>P</given-names></string-name>, <string-name><surname>Allen</surname><given-names>LA</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Ferrucci</surname><given-names>L</given-names></string-name>, <string-name><surname>Forman</surname><given-names>DE</given-names></string-name>. <article-title>Frailty assessment in the cardiovascular care of older adults</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>747</fpage>–<lpage>762</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.070</pub-id>
<pub-id pub-id-type="pmid">24291279</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0003"><string-name><surname>Ijaz</surname><given-names>N</given-names></string-name>, <string-name><surname>Buta</surname><given-names>B</given-names></string-name>, <string-name><surname>Xue</surname><given-names>QL</given-names></string-name>, <string-name><surname>Mohess</surname><given-names>DT</given-names></string-name>, <string-name><surname>Bushan</surname><given-names>A</given-names></string-name>, <string-name><surname>Tran</surname><given-names>H</given-names></string-name>, <string-name><surname>Batchelor</surname><given-names>W</given-names></string-name>, <string-name><surname>deFilippi</surname><given-names>CR</given-names></string-name>, <string-name><surname>Walston</surname><given-names>JD</given-names></string-name>, <string-name><surname>Bandeen‐Roche</surname><given-names>K</given-names></string-name>, et al. <article-title>Interventions for frailty among older adults with cardiovascular disease: JACC state‐of‐the‐art review</article-title>. <source>J Am Coll Cardiol</source>. <year>2022</year>;<volume>79</volume>:<fpage>482</fpage>–<lpage>503</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2021.11.029</pub-id>
<pub-id pub-id-type="pmid">35115105</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0004"><string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Virani</surname><given-names>SS</given-names></string-name>, <string-name><surname>Callaway</surname><given-names>CW</given-names></string-name>, <string-name><surname>Chamberlain</surname><given-names>AM</given-names></string-name>, <string-name><surname>Chang</surname><given-names>AR</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Chiuve</surname><given-names>SE</given-names></string-name>, <string-name><surname>Cushman</surname><given-names>M</given-names></string-name>, <string-name><surname>Delling</surname><given-names>FN</given-names></string-name>, <string-name><surname>Deo</surname><given-names>R</given-names></string-name>, et al. <article-title>Heart disease and stroke statistics‐2018 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2018</year>;<volume>137</volume>:<fpage>e67</fpage>–<lpage>e492</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000558</pub-id>
<pub-id pub-id-type="pmid">29386200</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0005"><string-name><surname>Singh</surname><given-names>M</given-names></string-name>, <string-name><surname>Rihal</surname><given-names>CS</given-names></string-name>, <string-name><surname>Lennon</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name><surname>Nair</surname><given-names>KS</given-names></string-name>, <string-name><surname>Roger</surname><given-names>VL</given-names></string-name>. <article-title>Influence of frailty and health status on outcomes in patients with coronary disease undergoing percutaneous revascularization</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2011</year>;<volume>4</volume>:<fpage>496</fpage>–<lpage>502</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.111.961375</pub-id>
<pub-id pub-id-type="pmid">21878670</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0006"><string-name><surname>Wang</surname><given-names>TY</given-names></string-name>, <string-name><surname>Gutierrez</surname><given-names>A</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>. <article-title>Percutaneous coronary intervention in the elderly</article-title>. <source>Nat Rev Cardiol</source>. <year>2011</year>;<volume>8</volume>:<fpage>79</fpage>–<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrcardio.2010.184</pub-id>
<pub-id pub-id-type="pmid">21139558</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0007"><string-name><surname>Hempenius</surname><given-names>L</given-names></string-name>, <string-name><surname>Slaets</surname><given-names>JP</given-names></string-name>, <string-name><surname>Boelens</surname><given-names>MA</given-names></string-name>, <string-name><surname>van Asselt</surname><given-names>DZ</given-names></string-name>, <string-name><surname>de Bock</surname><given-names>GH</given-names></string-name>, <string-name><surname>Wiggers</surname><given-names>T</given-names></string-name>, <string-name><surname>van Leeuwen</surname><given-names>BL</given-names></string-name>. <article-title>Inclusion of frail elderly patients in clinical trials: solutions to the problems</article-title>. <source>J Geriatr Oncol</source>. <year>2013</year>;<volume>4</volume>:<fpage>26</fpage>–<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jgo.2012.08.004</pub-id>
<pub-id pub-id-type="pmid">24071489</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0008"><string-name><surname>Knickman</surname><given-names>JR</given-names></string-name>, <string-name><surname>Snell</surname><given-names>EK</given-names></string-name>. <article-title>The 2030 problem: caring for aging baby boomers</article-title>. <source>Health Serv Res</source>. <year>2002</year>;<volume>37</volume>:<fpage>849</fpage>–<lpage>884</lpage>. doi: <pub-id pub-id-type="doi">10.1034/j.1600-0560.2002.56.x</pub-id>
<pub-id pub-id-type="pmid">12236388</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0009"><string-name><surname>Rodes‐Cabau</surname><given-names>J</given-names></string-name>, <string-name><surname>Webb</surname><given-names>JG</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>A</given-names></string-name>, <string-name><surname>Ye</surname><given-names>J</given-names></string-name>, <string-name><surname>Dumont</surname><given-names>E</given-names></string-name>, <string-name><surname>Feindel</surname><given-names>CM</given-names></string-name>, <string-name><surname>Osten</surname><given-names>M</given-names></string-name>, <string-name><surname>Natarajan</surname><given-names>MK</given-names></string-name>, <string-name><surname>Velianou</surname><given-names>JL</given-names></string-name>, <string-name><surname>Martucci</surname><given-names>G</given-names></string-name>, et al. <article-title>Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>1080</fpage>–<lpage>1090</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2009.12.014</pub-id>
<pub-id pub-id-type="pmid">20096533</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0010"><string-name><surname>Alonso Salinas</surname><given-names>GL</given-names></string-name>, <string-name><surname>Sanmartin Fernandez</surname><given-names>M</given-names></string-name>, <string-name><surname>Pascual Izco</surname><given-names>M</given-names></string-name>, <string-name><surname>Marco Del Castillo</surname><given-names>A</given-names></string-name>, <string-name><surname>Rincon Diaz</surname><given-names>LM</given-names></string-name>, <string-name><surname>Lozano Granero</surname><given-names>C</given-names></string-name>, <string-name><surname>Valverde Gomez</surname><given-names>M</given-names></string-name>, <string-name><surname>Pastor Pueyo</surname><given-names>P</given-names></string-name>, <string-name><surname>Del Val</surname><given-names>MD</given-names></string-name>, <string-name><surname>Pardo Sanz</surname><given-names>A</given-names></string-name>, et al. <article-title>Frailty predicts major bleeding within 30 days in elderly patients with acute coronary syndrome</article-title>. <source>Int J Cardiol</source>. <year>2016</year>;<volume>222</volume>:<fpage>590</fpage>–<lpage>593</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijcard.2016.07.268</pub-id>
<pub-id pub-id-type="pmid">27513656</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0011"><string-name><surname>Dodson</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hochman</surname><given-names>JS</given-names></string-name>, <string-name><surname>Roe</surname><given-names>MT</given-names></string-name>, <string-name><surname>Chen</surname><given-names>AY</given-names></string-name>, <string-name><surname>Chaudhry</surname><given-names>SI</given-names></string-name>, <string-name><surname>Katz</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhong</surname><given-names>H</given-names></string-name>, <string-name><surname>Radford</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Bagai</surname><given-names>A</given-names></string-name>, et al. <article-title>The association of frailty with in‐hospital bleeding among older adults with acute myocardial Infarction: insights from the ACTION registry</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2018</year>;<volume>11</volume>:<fpage>2287</fpage>–<lpage>2296</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2018.08.028</pub-id>
<pub-id pub-id-type="pmid">30466828</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0012"><string-name><surname>Genereux</surname><given-names>P</given-names></string-name>, <string-name><surname>Giustino</surname><given-names>G</given-names></string-name>, <string-name><surname>Witzenbichler</surname><given-names>B</given-names></string-name>, <string-name><surname>Weisz</surname><given-names>G</given-names></string-name>, <string-name><surname>Stuckey</surname><given-names>TD</given-names></string-name>, <string-name><surname>Rinaldi</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Neumann</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Metzger</surname><given-names>DC</given-names></string-name>, <string-name><surname>Henry</surname><given-names>TD</given-names></string-name>, <string-name><surname>Cox</surname><given-names>DA</given-names></string-name>, et al. <article-title>Incidence, predictors, and impact of post‐discharge bleeding after percutaneous coronary intervention</article-title>. <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>:<fpage>1036</fpage>–<lpage>1045</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2015.06.1323</pub-id>
<pub-id pub-id-type="pmid">26314532</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0013"><string-name><surname>Lee</surname><given-names>SY</given-names></string-name>, <string-name><surname>Hong</surname><given-names>MK</given-names></string-name>, <string-name><surname>Palmerini</surname><given-names>T</given-names></string-name>, <string-name><surname>Kim</surname><given-names>HS</given-names></string-name>, <string-name><surname>Valgimigli</surname><given-names>M</given-names></string-name>, <string-name><surname>Feres</surname><given-names>F</given-names></string-name>, <string-name><surname>Colombo</surname><given-names>A</given-names></string-name>, <string-name><surname>Gilard</surname><given-names>M</given-names></string-name>, <string-name><surname>Shin</surname><given-names>DH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JS</given-names></string-name>, et al. <article-title>Short‐term versus long‐term dual antiplatelet therapy after drug‐eluting stent implantation in elderly patients: a meta‐analysis of individual participant data from 6 randomized trials</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2018</year>;<volume>11</volume>:<fpage>435</fpage>–<lpage>443</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2017.10.015</pub-id>
<pub-id pub-id-type="pmid">29454730</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0014"><string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Normand</surname><given-names>SL</given-names></string-name>, <string-name><surname>Gershlick</surname><given-names>AH</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Rinaldi</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>:<fpage>1735</fpage>–<lpage>1749</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.3775</pub-id>
<pub-id pub-id-type="pmid">27022822</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0015"><string-name><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name><surname>Schneeweiss</surname><given-names>S</given-names></string-name>, <string-name><surname>Glynn</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Lipsitz</surname><given-names>LA</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name>, <string-name><surname>Avorn</surname><given-names>J</given-names></string-name>. <article-title>Measuring frailty in Medicare data: development and validation of a claims‐based frailty index</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2018</year>;<volume>73</volume>:<fpage>980</fpage>–<lpage>987</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/glx229</pub-id>
<pub-id pub-id-type="pmid">29244057</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0016"><string-name><surname>Gilbert</surname><given-names>T</given-names></string-name>, <string-name><surname>Neuburger</surname><given-names>J</given-names></string-name>, <string-name><surname>Kraindler</surname><given-names>J</given-names></string-name>, <string-name><surname>Keeble</surname><given-names>E</given-names></string-name>, <string-name><surname>Smith</surname><given-names>P</given-names></string-name>, <string-name><surname>Ariti</surname><given-names>C</given-names></string-name>, <string-name><surname>Arora</surname><given-names>S</given-names></string-name>, <string-name><surname>Street</surname><given-names>A</given-names></string-name>, <string-name><surname>Parker</surname><given-names>S</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>HC</given-names></string-name>, et al. <article-title>Development and validation of a hospital frailty risk score focusing on older people in acute care settings using electronic hospital records: an observational study</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>1775</fpage>–<lpage>1782</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)30668-8</pub-id>
<pub-id pub-id-type="pmid">29706364</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0017"><string-name><surname>Segal</surname><given-names>JB</given-names></string-name>, <string-name><surname>Chang</surname><given-names>HY</given-names></string-name>, <string-name><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name><surname>Walston</surname><given-names>JD</given-names></string-name>, <string-name><surname>Carlson</surname><given-names>MC</given-names></string-name>, <string-name><surname>Varadhan</surname><given-names>R</given-names></string-name>. <article-title>Development of a claims‐based frailty indicator anchored to a well‐established frailty phenotype</article-title>. <source>Med Care</source>. <year>2017</year>;<volume>55</volume>:<fpage>716</fpage>–<lpage>722</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MLR.0000000000000729</pub-id>
<pub-id pub-id-type="pmid">28437320</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0018"><string-name><surname>Segal</surname><given-names>JB</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name><surname>Roth</surname><given-names>DL</given-names></string-name>, <string-name><surname>Varadhan</surname><given-names>R</given-names></string-name>. <article-title>External validation of the claims‐based frailty index in the national health and aging trends study cohort</article-title>. <source>Am J Epidemiol</source>. <year>2017</year>;<volume>186</volume>:<fpage>745</fpage>–<lpage>747</lpage>. doi: <pub-id pub-id-type="doi">10.1093/aje/kwx257</pub-id>
<pub-id pub-id-type="pmid">28938711</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0019"><string-name><surname>Shashikumar</surname><given-names>SA</given-names></string-name>, <string-name><surname>Huang</surname><given-names>K</given-names></string-name>, <string-name><surname>Konetzka</surname><given-names>RT</given-names></string-name>, <string-name><surname>Joynt Maddox</surname><given-names>KE</given-names></string-name>. <article-title>Claims‐based frailty indices: a systematic review</article-title>. <source>Med Care</source>. <year>2020</year>;<volume>58</volume>:<fpage>815</fpage>–<lpage>825</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MLR.0000000000001359</pub-id>
<pub-id pub-id-type="pmid">32520767</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0020"><string-name><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name><surname>Glynn</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Avorn</surname><given-names>J</given-names></string-name>, <string-name><surname>Lipsitz</surname><given-names>LA</given-names></string-name>, <string-name><surname>Rockwood</surname><given-names>K</given-names></string-name>, <string-name><surname>Pawar</surname><given-names>A</given-names></string-name>, <string-name><surname>Schneeweiss</surname><given-names>S</given-names></string-name>. <article-title>Validation of a claims‐based frailty index against physical performance and adverse health outcomes in the health and retirement study</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2019</year>;<volume>74</volume>:<fpage>1271</fpage>–<lpage>1276</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/gly197</pub-id>
<pub-id pub-id-type="pmid">30165612</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0021"><string-name><surname>Kundi</surname><given-names>H</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>DS</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Impact of a claims‐based frailty indicator on the prediction of long‐term mortality after transcatheter aortic valve replacement in Medicare beneficiaries</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2018</year>;<volume>11</volume>:<elocation-id>e005048</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.118.005048</pub-id><pub-id pub-id-type="pmid">30354574</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0022"><string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Charest</surname><given-names>BR</given-names></string-name>, <string-name><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>DB</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, et al. <article-title>The role of frailty in identifying benefit from transcatheter versus surgical aortic valve replacement</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>:<elocation-id>e008566</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.121.008566</pub-id><pub-id pub-id-type="pmid">34779656</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0023"><string-name><surname>Kundi</surname><given-names>H</given-names></string-name>, <string-name><surname>Wadhera</surname><given-names>RK</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Kazi</surname><given-names>DS</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Association of frailty with 30‐day outcomes for acute myocardial infarction, heart failure, and pneumonia among elderly adults</article-title>. <source>JAMA Cardiol</source>. <year>2019</year>;<volume>4</volume>:<fpage>1084</fpage>–<lpage>1091</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamacardio.2019.3511</pub-id>
<pub-id pub-id-type="pmid">31553402</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0024"><string-name><surname>Kundi</surname><given-names>H</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>MR</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>DS</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Choi</surname><given-names>E</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort</article-title>. <source>Eur Heart J</source>. <year>2019</year>;<volume>40</volume>:<fpage>2231</fpage>–<lpage>2239</lpage>. doi: <pub-id pub-id-type="doi">10.1093/eurheartj/ehz187</pub-id>
<pub-id pub-id-type="pmid">30977798</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0025"><string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>, <string-name><surname>Driscoll‐Shempp</surname><given-names>P</given-names></string-name>, <string-name><surname>Cutlip</surname><given-names>DE</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Normand</surname><given-names>SL</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>2155</fpage>–<lpage>2166</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1409312</pub-id>
<pub-id pub-id-type="pmid">25399658</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0026"><string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>J</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Validating the use of registries and claims data to support randomized trials: rationale and design of the Extending Trial‐Based Evaluations of Medical Therapies using Novel Sources of Data (EXTEND) Study</article-title>. <source>Am Heart J</source>. <year>2019</year>;<volume>212</volume>:<fpage>64</fpage>–<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ahj.2019.02.007</pub-id>
<pub-id pub-id-type="pmid">30953936</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0027"><string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>CM</given-names></string-name>, et al. <article-title>Use of administrative claims data to estimate treatment effects for 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention: findings from the EXTEND‐DAPT study</article-title>. <source>Circulation</source>. <year>2020</year>;<volume>142</volume>:<fpage>306</fpage>–<lpage>308</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047729</pub-id>
<pub-id pub-id-type="pmid">32687440</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0028"><string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Comparability of event adjudication versus administrative billing claims for outcome ascertainment in the DAPT study: findings from the EXTEND‐DAPT study</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2021</year>;<volume>14</volume>:<elocation-id>e006589</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.120.006589</pub-id><pub-id pub-id-type="pmid">33435731</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0029"><string-name><surname>Fried</surname><given-names>LP</given-names></string-name>, <string-name><surname>Tangen</surname><given-names>CM</given-names></string-name>, <string-name><surname>Walston</surname><given-names>J</given-names></string-name>, <string-name><surname>Newman</surname><given-names>AB</given-names></string-name>, <string-name><surname>Hirsch</surname><given-names>C</given-names></string-name>, <string-name><surname>Gottdiener</surname><given-names>J</given-names></string-name>, <string-name><surname>Seeman</surname><given-names>T</given-names></string-name>, <string-name><surname>Tracy</surname><given-names>R</given-names></string-name>, <string-name><surname>Kop</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Burke</surname><given-names>G</given-names></string-name>, et al. <article-title>Frailty in older adults: evidence for a phenotype</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2001</year>;<volume>56</volume>:<fpage>M146</fpage>–<lpage>M156</lpage>. doi: <pub-id pub-id-type="doi">10.1093/gerona/56.3.M146</pub-id>
<pub-id pub-id-type="pmid">11253156</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0030"><string-name><surname>Kundi</surname><given-names>H</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Pinto</surname><given-names>DS</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>The value of claims‐based nontraditional risk factors in predicting long‐term mortality after MitraClip procedure</article-title>. <source>Can J Cardiol</source>. <year>2018</year>;<volume>34</volume>:<fpage>1648</fpage>–<lpage>1654</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cjca.2018.10.002</pub-id>
<pub-id pub-id-type="pmid">30527154</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0031"><collab collab-type="authors">GUSTO investigators</collab>
. <article-title>An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>1993</year>;<volume>329</volume>:<fpage>673</fpage>–<lpage>682</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJM199309023291001</pub-id>
<pub-id pub-id-type="pmid">8204123</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0032"><string-name><surname>Mehran</surname><given-names>R</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Nikolsky</surname><given-names>E</given-names></string-name>, <string-name><surname>Clayton</surname><given-names>T</given-names></string-name>, <string-name><surname>Dangas</surname><given-names>GD</given-names></string-name>, <string-name><surname>Kirtane</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Parise</surname><given-names>H</given-names></string-name>, <string-name><surname>Fahy</surname><given-names>M</given-names></string-name>, <string-name><surname>Manoukian</surname><given-names>SV</given-names></string-name>, <string-name><surname>Feit</surname><given-names>F</given-names></string-name>, et al. <article-title>A risk score to predict bleeding in patients with acute coronary syndromes</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>55</volume>:<fpage>2556</fpage>–<lpage>2566</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2009.09.076</pub-id>
<pub-id pub-id-type="pmid">20513595</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0033"><string-name><surname>Fine</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gray</surname><given-names>RJ</given-names></string-name>. <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source>. <year>1999</year>;<volume>94</volume>:<fpage>496</fpage>–<lpage>509</lpage>. doi: <pub-id pub-id-type="doi">10.1080/01621459.1999.10474144</pub-id>
</mixed-citation>
              </ref>
              <ref id="jah38582-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0034"><string-name><surname>Krumholz</surname><given-names>HM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name><surname>Drye</surname><given-names>EE</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ross</surname><given-names>JS</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, <string-name><surname>Nallamothu</surname><given-names>BK</given-names></string-name>, <string-name><surname>Lichtman</surname><given-names>JH</given-names></string-name>, <string-name><surname>Havranek</surname><given-names>EP</given-names></string-name>, et al. <article-title>Reduction in acute myocardial infarction mortality in the United States: risk‐standardized mortality rates from 1995–2006</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>302</volume>:<fpage>767</fpage>–<lpage>773</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2009.1178</pub-id>
<pub-id pub-id-type="pmid">19690309</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0035"><string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Pan</surname><given-names>W</given-names></string-name>, <string-name><surname>Saver</surname><given-names>JL</given-names></string-name>, <string-name><surname>Smith</surname><given-names>EE</given-names></string-name>, <string-name><surname>Reeves</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Broderick</surname><given-names>JP</given-names></string-name>, <string-name><surname>Kleindorfer</surname><given-names>DO</given-names></string-name>, <string-name><surname>Sacco</surname><given-names>RL</given-names></string-name>, <string-name><surname>Olson</surname><given-names>DM</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, et al. <article-title>Comparison of 30‐day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>308</volume>:<fpage>257</fpage>–<lpage>264</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2012.7870</pub-id>
<pub-id pub-id-type="pmid">22797643</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0036"><string-name><surname>Stukel</surname><given-names>TA</given-names></string-name>, <string-name><surname>Lucas</surname><given-names>FL</given-names></string-name>, <string-name><surname>Wennberg</surname><given-names>DE</given-names></string-name>. <article-title>Long‐term outcomes of regional variations in intensity of invasive vs medical management of Medicare patients with acute myocardial infarction</article-title>. <source>JAMA</source>. <year>2005</year>;<volume>293</volume>:<fpage>1329</fpage>–<lpage>1337</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.293.11.1329</pub-id>
<pub-id pub-id-type="pmid">15769966</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0037"><string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>ED</given-names></string-name>, <string-name><surname>Messenger</surname><given-names>JC</given-names></string-name>, <string-name><surname>Rumsfeld</surname><given-names>JS</given-names></string-name>, <string-name><surname>Weintraub</surname><given-names>WS</given-names></string-name>, <string-name><surname>Anstrom</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Eisenstein</surname><given-names>EL</given-names></string-name>, <string-name><surname>Milford‐Beland</surname><given-names>S</given-names></string-name>, <string-name><surname>Grau‐Sepulveda</surname><given-names>MV</given-names></string-name>, <string-name><surname>Booth</surname><given-names>ME</given-names></string-name>, et al. <article-title>Linking the National Cardiovascular Data Registry CathPCI registry with Medicare claims data: validation of a longitudinal cohort of elderly patients undergoing cardiac catheterization</article-title>. <source>Circ Cardiovasc Qual Outcomes</source>. <year>2012</year>;<volume>5</volume>:<fpage>134</fpage>–<lpage>140</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.111.963280</pub-id>
<pub-id pub-id-type="pmid">22253370</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0038"><string-name><surname>Weintraub</surname><given-names>WS</given-names></string-name>, <string-name><surname>Bellows</surname><given-names>BK</given-names></string-name>. <article-title>Evaluating clinical outcomes from administrative databases</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2020</year>;<volume>13</volume>:<fpage>1786</fpage>–<lpage>1788</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2020.04.023</pub-id>
<pub-id pub-id-type="pmid">32682675</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0039"><string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Gersh</surname><given-names>BJ</given-names></string-name>. <article-title>Do current clinical trials meet society's needs?: a critical review of recent evidence</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>1615</fpage>–<lpage>1628</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2014.08.008</pub-id>
<pub-id pub-id-type="pmid">25301467</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0040"><string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Valsdottir</surname><given-names>LR</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Kazi</surname><given-names>DS</given-names></string-name>, et al. <article-title>Use of administrative claims to assess outcomes and treatment effect in randomized clinical trials for transcatheter aortic valve replacement: findings from the EXTEND study</article-title>. <source>Circulation</source>. <year>2020</year>;<volume>142</volume>:<fpage>203</fpage>–<lpage>213</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046159</pub-id>
<pub-id pub-id-type="pmid">32436390</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0041"><string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Kazi</surname><given-names>DS</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>JM</given-names></string-name>, <string-name><surname>Popma</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Yeh</surname><given-names>RW</given-names></string-name>. <article-title>Validation of administrative claims to ascertain outcomes in pivotal trials of transcatheter aortic valve replacement</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2020</year>;<volume>13</volume>:<fpage>1777</fpage>–<lpage>1785</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jcin.2020.03.049</pub-id>
<pub-id pub-id-type="pmid">32682677</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0042"><string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Orkaby</surname><given-names>AR</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Charest</surname><given-names>BR</given-names></string-name>, <string-name><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>DB</given-names></string-name>, <string-name><surname>Spertus</surname><given-names>JA</given-names></string-name>, <string-name><surname>Gerszten</surname><given-names>RE</given-names></string-name>, et al. <article-title>Identification of frailty using a claims‐based frailty index in the CoreValve studies: findings from the EXTEND‐FRAILTY study</article-title>. <source>J Am Heart Assoc</source>. <year>2021</year>;<volume>10</volume>:<elocation-id>e022150</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.121.022150</pub-id><pub-id pub-id-type="pmid">34585597</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0043"><string-name><surname>Bebb</surname><given-names>O</given-names></string-name>, <string-name><surname>Smith</surname><given-names>FG</given-names></string-name>, <string-name><surname>Clegg</surname><given-names>A</given-names></string-name>, <string-name><surname>Hall</surname><given-names>M</given-names></string-name>, <string-name><surname>Gale</surname><given-names>CP</given-names></string-name>. <article-title>Frailty and acute coronary syndrome: a structured literature review</article-title>. <source>Eur Heart J Acute Cardiovasc Care</source>. <year>2018</year>;<volume>7</volume>:<fpage>166</fpage>–<lpage>175</lpage>. doi: <pub-id pub-id-type="doi">10.1177/2048872617700873</pub-id>
<pub-id pub-id-type="pmid">29064267</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0044"><string-name><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name><surname>Goodman</surname><given-names>SG</given-names></string-name>, <string-name><surname>Yan</surname><given-names>AT</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>KP</given-names></string-name>, <string-name><surname>Wong</surname><given-names>CL</given-names></string-name>, <string-name><surname>Cheema</surname><given-names>AN</given-names></string-name>, <string-name><surname>Udell</surname><given-names>JA</given-names></string-name>, <string-name><surname>Kaul</surname><given-names>P</given-names></string-name>, <string-name><surname>D'Souza</surname><given-names>M</given-names></string-name>, <string-name><surname>Hyun</surname><given-names>K</given-names></string-name>, et al. <article-title>Frailty and outcomes after myocardial infarction: insights from the CONCORDANCE registry</article-title>. <source>J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>:<elocation-id>e009859</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.118.009859</pub-id><pub-id pub-id-type="pmid">30371219</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0045"><string-name><surname>Tse</surname><given-names>G</given-names></string-name>, <string-name><surname>Gong</surname><given-names>M</given-names></string-name>, <string-name><surname>Nunez</surname><given-names>J</given-names></string-name>, <string-name><surname>Sanchis</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name>, <string-name><surname>Ali‐Hasan‐Al‐Saegh</surname><given-names>S</given-names></string-name>, <string-name><surname>Wong</surname><given-names>WT</given-names></string-name>, <string-name><surname>Wong</surname><given-names>SH</given-names></string-name>, <string-name><surname>Wu</surname><given-names>WKK</given-names></string-name>, <string-name><surname>Bazoukis</surname><given-names>G</given-names></string-name>, et al. <article-title>Frailty and mortality outcomes after percutaneous coronary intervention: a systematic review and meta‐analysis</article-title>. <source>J Am Med Dir Assoc</source>. <year>2017</year>;<volume>18</volume>:<fpage>1097</fpage>.e1. doi: <pub-id pub-id-type="doi">10.1016/j.jamda.2017.09.002</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0046"><string-name><surname>Nishihira</surname><given-names>K</given-names></string-name>, <string-name><surname>Yoshioka</surname><given-names>G</given-names></string-name>, <string-name><surname>Kuriyama</surname><given-names>N</given-names></string-name>, <string-name><surname>Ogata</surname><given-names>K</given-names></string-name>, <string-name><surname>Kimura</surname><given-names>T</given-names></string-name>, <string-name><surname>Matsuura</surname><given-names>H</given-names></string-name>, <string-name><surname>Furugen</surname><given-names>M</given-names></string-name>, <string-name><surname>Koiwaya</surname><given-names>H</given-names></string-name>, <string-name><surname>Watanabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Shibata</surname><given-names>Y</given-names></string-name>. <article-title>Impact of frailty on outcomes in elderly patients with acute myocardial infarction who undergo percutaneous coronary intervention</article-title>. <source>Eur Heart J Qual Care Clin Outcomes</source>. <year>2021</year>;<volume>7</volume>:<fpage>189</fpage>–<lpage>197</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ehjqcco/qcaa018</pub-id>
<pub-id pub-id-type="pmid">32142106</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0047"><string-name><surname>Ekerstad</surname><given-names>N</given-names></string-name>, <string-name><surname>Swahn</surname><given-names>E</given-names></string-name>, <string-name><surname>Janzon</surname><given-names>M</given-names></string-name>, <string-name><surname>Alfredsson</surname><given-names>J</given-names></string-name>, <string-name><surname>Lofmark</surname><given-names>R</given-names></string-name>, <string-name><surname>Lindenberger</surname><given-names>M</given-names></string-name>, <string-name><surname>Carlsson</surname><given-names>P</given-names></string-name>. <article-title>Frailty is independently associated with short‐term outcomes for elderly patients with non‐ST‐segment elevation myocardial infarction</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>2397</fpage>–<lpage>2404</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.025452</pub-id>
<pub-id pub-id-type="pmid">22064593</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0048"><string-name><surname>Matsuzawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Konishi</surname><given-names>M</given-names></string-name>, <string-name><surname>Akiyama</surname><given-names>E</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>H</given-names></string-name>, <string-name><surname>Nakayama</surname><given-names>N</given-names></string-name>, <string-name><surname>Kiyokuni</surname><given-names>M</given-names></string-name>, <string-name><surname>Sumita</surname><given-names>S</given-names></string-name>, <string-name><surname>Ebina</surname><given-names>T</given-names></string-name>, <string-name><surname>Kosuge</surname><given-names>M</given-names></string-name>, <string-name><surname>Hibi</surname><given-names>K</given-names></string-name>, et al. <article-title>Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction</article-title>. <source>J Am Coll Cardiol</source>. <year>2013</year>;<volume>61</volume>:<fpage>1964</fpage>–<lpage>1972</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.020</pub-id>
<pub-id pub-id-type="pmid">23500222</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0049"><string-name><surname>Putthapiban</surname><given-names>P</given-names></string-name>, <string-name><surname>Vutthikraivit</surname><given-names>W</given-names></string-name>, <string-name><surname>Rattanawong</surname><given-names>P</given-names></string-name>, <string-name><surname>Sukhumthammarat</surname><given-names>W</given-names></string-name>, <string-name><surname>Kanjanahattakij</surname><given-names>N</given-names></string-name>, <string-name><surname>Kewcharoen</surname><given-names>J</given-names></string-name>, <string-name><surname>Amanullah</surname><given-names>A</given-names></string-name>. <article-title>Association of frailty with all‐cause mortality and bleeding among elderly patients with acute myocardial infarction: a systematic review and meta‐analysis</article-title>. <source>J Geriatr Cardiol</source>. <year>2020</year>;<volume>17</volume>:<fpage>270</fpage>–<lpage>278</lpage>.<pub-id pub-id-type="pmid">32547610</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0050"><string-name><surname>Alonso Salinas</surname><given-names>GL</given-names></string-name>, <string-name><surname>Sanmartin</surname><given-names>M</given-names></string-name>, <string-name><surname>Pascual Izco</surname><given-names>M</given-names></string-name>, <string-name><surname>Rincon</surname><given-names>LM</given-names></string-name>, <string-name><surname>Martin‐Acuna</surname><given-names>A</given-names></string-name>, <string-name><surname>Pastor Pueyo</surname><given-names>P</given-names></string-name>, <string-name><surname>Del Val</surname><given-names>MD</given-names></string-name>, <string-name><surname>Marco Del Castillo</surname><given-names>A</given-names></string-name>, <string-name><surname>Recio‐Mayoral</surname><given-names>A</given-names></string-name>, <string-name><surname>Martin‐Asenjo</surname><given-names>R</given-names></string-name>, et al. <article-title>The role of frailty in acute coronary syndromes in the elderly</article-title>. <source>Gerontology</source>. <year>2018</year>;<volume>64</volume>:<fpage>422</fpage>–<lpage>429</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000488390</pub-id>
<pub-id pub-id-type="pmid">29860244</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="miscellaneous" id="jah38582-cit-0051"><article-title>21st Century Cures Act</article-title>. <year>2020</year>. U.S. Food &amp; Drug Administration. Accessed November 24, 2022. <ext-link xlink:href="https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act" ext-link-type="uri">https://www.fda.gov/regulatory‐information/selected‐amendments‐fdc‐act/21st‐century‐cures‐act</ext-link>.</mixed-citation>
              </ref>
              <ref id="jah38582-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0052"><string-name><surname>Frobert</surname><given-names>O</given-names></string-name>, <string-name><surname>Lagerqvist</surname><given-names>B</given-names></string-name>, <string-name><surname>Olivecrona</surname><given-names>GK</given-names></string-name>, <string-name><surname>Omerovic</surname><given-names>E</given-names></string-name>, <string-name><surname>Gudnason</surname><given-names>T</given-names></string-name>, <string-name><surname>Maeng</surname><given-names>M</given-names></string-name>, <string-name><surname>Aasa</surname><given-names>M</given-names></string-name>, <string-name><surname>Angeras</surname><given-names>O</given-names></string-name>, <string-name><surname>Calais</surname><given-names>F</given-names></string-name>, <string-name><surname>Danielewicz</surname><given-names>M</given-names></string-name>, et al. <article-title>Thrombus aspiration during ST‐segment elevation myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>369</volume>:<fpage>1587</fpage>–<lpage>1597</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1308789</pub-id>
<pub-id pub-id-type="pmid">23991656</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0053"><string-name><surname>Ma</surname><given-names>Q</given-names></string-name>, <string-name><surname>Chung</surname><given-names>H</given-names></string-name>, <string-name><surname>Shambhu</surname><given-names>S</given-names></string-name>, <string-name><surname>Roe</surname><given-names>M</given-names></string-name>, <string-name><surname>Cziraky</surname><given-names>M</given-names></string-name>, <string-name><surname>Jones</surname><given-names>WS</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>K</given-names></string-name>. <article-title>Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health</article-title>. <source>Clin Trials</source>. <year>2019</year>;<volume>16</volume>:<fpage>419</fpage>–<lpage>430</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1740774519846853</pub-id>
<pub-id pub-id-type="pmid">31081367</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0054"><string-name><surname>Berger</surname><given-names>PB</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Fuster</surname><given-names>V</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Fox</surname><given-names>KA</given-names></string-name>, <string-name><surname>Shao</surname><given-names>M</given-names></string-name>, <string-name><surname>Brennan</surname><given-names>DM</given-names></string-name>, <string-name><surname>Hacke</surname><given-names>W</given-names></string-name>, <string-name><surname>Montalescot</surname><given-names>G</given-names></string-name>, <string-name><surname>Steinhubl</surname><given-names>SR</given-names></string-name>, et al. <article-title>Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial</article-title>. <source>Circulation</source>. <year>2010</year>;<volume>121</volume>:<fpage>2575</fpage>–<lpage>2583</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.895342</pub-id>
<pub-id pub-id-type="pmid">20516378</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0055"><string-name><surname>Walston</surname><given-names>J</given-names></string-name>, <string-name><surname>McBurnie</surname><given-names>MA</given-names></string-name>, <string-name><surname>Newman</surname><given-names>A</given-names></string-name>, <string-name><surname>Tracy</surname><given-names>RP</given-names></string-name>, <string-name><surname>Kop</surname><given-names>WJ</given-names></string-name>, <string-name><surname>Hirsch</surname><given-names>CH</given-names></string-name>, <string-name><surname>Gottdiener</surname><given-names>J</given-names></string-name>, <string-name><surname>Fried</surname><given-names>LP</given-names></string-name>. <article-title>Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study</article-title>. <source>Arch Intern Med</source>. <year>2002</year>;<volume>162</volume>:<fpage>2333</fpage>–<lpage>2341</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archinte.162.20.2333</pub-id>
<pub-id pub-id-type="pmid">12418947</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0056"><string-name><surname>Butala</surname><given-names>NM</given-names></string-name>, <string-name><surname>Faridi</surname><given-names>KF</given-names></string-name>, <string-name><surname>Tamez</surname><given-names>H</given-names></string-name>, <string-name><surname>Strom</surname><given-names>JB</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name><surname>Secemsky</surname><given-names>EA</given-names></string-name>, <string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>Kereiakes</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>JP</given-names></string-name>, et al. <article-title>Estimation of DAPT study treatment effects in contemporary clinical practice: findings from the EXTEND‐DAPT study</article-title>. <source>Circulation</source>. <year>2022</year>;<volume>145</volume>:<fpage>97</fpage>–<lpage>106</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.056878</pub-id>
<pub-id pub-id-type="pmid">34743530</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0057"><string-name><surname>Rockwood</surname><given-names>K</given-names></string-name>, <string-name><surname>Song</surname><given-names>X</given-names></string-name>, <string-name><surname>MacKnight</surname><given-names>C</given-names></string-name>, <string-name><surname>Bergman</surname><given-names>H</given-names></string-name>, <string-name><surname>Hogan</surname><given-names>DB</given-names></string-name>, <string-name><surname>McDowell</surname><given-names>I</given-names></string-name>, <string-name><surname>Mitnitski</surname><given-names>A</given-names></string-name>. <article-title>A global clinical measure of fitness and frailty in elderly people</article-title>. <source>CMAJ</source>. <year>2005</year>;<volume>173</volume>:<fpage>489</fpage>–<lpage>495</lpage>. doi: <pub-id pub-id-type="doi">10.1503/cmaj.050051</pub-id>
<pub-id pub-id-type="pmid">16129869</pub-id></mixed-citation>
              </ref>
              <ref id="jah38582-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="jah38582-cit-0058"><string-name><surname>Angelini</surname><given-names>F</given-names></string-name>, <string-name><surname>Franchin</surname><given-names>L</given-names></string-name>, <string-name><surname>Bocchino</surname><given-names>PP</given-names></string-name>, <string-name><surname>Morici</surname><given-names>N</given-names></string-name>, <string-name><surname>Wanha</surname><given-names>W</given-names></string-name>, <string-name><surname>Savonitto</surname><given-names>S</given-names></string-name>, <string-name><surname>Trabattoni</surname><given-names>D</given-names></string-name>, <string-name><surname>Cerrato</surname><given-names>E</given-names></string-name>, <string-name><surname>Barbieri</surname><given-names>L</given-names></string-name>, <string-name><surname>Fortuni</surname><given-names>F</given-names></string-name>, et al. <article-title>In‐hospital outcomes in nonagenarian patients undergoing primary percutaneous coronary intervention</article-title>. <source>Minerva Cardiol Angiol</source>. <year>2022</year>. Online ahead of print. doi: <pub-id pub-id-type="doi">10.23736/S2724-5683.22.06167-1</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
